The next step should be to conduct a prospective study, with larger sample size and a fixed-dose protocol, comparing different imaging modalities with response assessment, especially for solid tumors with specific tumor biomarkers, such as functional MRI or prostate-specific membrane antigen PET/CT (for prostate cancer). The gene discussed is FOLH1; the disease is prostate carcinoma.